News

Shares of Amarin (NASDAQ: AMRN) skyrocketed 32.9% on Wednesday after the biopharmaceutical company announced strong preliminary fiscal fourth-quarter results, a new share-repurchase authorization, and encouraging 2024 guidance.

A strong end to Amarin's year

In a press release this morning, Amarin told investors it now expects fourth-quarter 2023 revenue of between $72 million and $74 million, far above analysts' consensus estimates for sales closer to $62 million. That would bring full-year 2023 revenue to between $304 million and $306 million, versus estimates for $294 million.

Amarin says it ended the year with roughly $321 million in cash and investments, with positive cash flow of $10 million for the year. That marks the company's sixth straight quarter of cash-positive or cash-neutral operations.

What's next for Amarin investors?

Amarin also announced a new conditional share repurchase agreement with Cantor Fitzgerald of up to $50 million of shares held in the form of American depositary shares (ADSs). Assuming the agreement receives the approvals of shareholders and the U.K. High Court, the company expects to complete the repurchases around the middle of 2024.

Finally, looking ahead in 2024, Amarin expects to further reduce operating expenses while delivering $40 million of annual savings related to the company's restructuring announced back in July 2023. The company implemented that move as its sole product, the cholesterol drug Vascepa, faces increasing competition from generic alternatives in the U.S. market. Amarin added that it will focus on preserving cash to "prudently invest in the right opportunities which are value additive."

That will likely mean reallocating capital toward its efforts on the European market, where Amarin still has plenty of work to do. But this was a big step in the right direction as investors worry about Amarin's future growth prospects, and shares responded in kind today.

Should you invest $1,000 in Amarin Plc right now?

Before you buy stock in Amarin Plc, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Amarin Plc wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

*Stock Advisor returns as of January 8, 2024

Steve Symington has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.